May 9, 2012 / 3:15 PM / 5 years ago

UPDATE 1-Dynavax sinks on discounted offering, CEO exit

May 9 (Reuters) - Shares of Dynavax Technologies Corp , which priced its public offering at a steep discount, fell as much as 22 percent a day after the biopharmaceutical company said its chief executive intends to step down.

Dynavax priced its public offering of 17.5 million shares at $4.25 each, a 17 percent discount to Tuesday's close, and said it plans to use the net proceeds for the anticipated launch of its experimental hepatitis B vaccine.

The company, which intends to independently launch the vaccine Heplisav in the United States, said on Tuesday it will begin looking for a successor to Chief Executive Dino Dina.

Dynavax had filed a marketing application with the U.S. Food and Drug Administration in April for the vaccine in adults aged 18 to 70 years.

Shares of the company fell 21 percent to $4 in morning trade on Wednesday on the Nasdaq.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below